Cue Biopharma Secures Funding, Expands Cell Therapy Focus

Event summary

  • Cue Biopharma raised $10.2 million via a public offering in Q4 2025.
  • The company entered a strategic collaboration and license agreement with ImmunoScape, receiving $9.5 million upfront and a 40% equity stake in ImmunoScape.
  • Cue Biopharma is advancing CUE-401, its lead asset for autoimmune and inflammatory diseases, towards Investigational New Drug (IND) readiness.
  • Research and development expenses increased significantly in 2025, primarily due to CUE-401 development and the ImmunoScape collaboration.

The big picture

Cue Biopharma’s strategic shift towards cell therapy development, coupled with the recent funding round, signals a broader industry trend of leveraging innovative technologies to address unmet needs in oncology. The ImmunoScape collaboration represents a significant bet on a new therapeutic modality, but also introduces dependencies and potential integration challenges. The company's ability to execute on this strategy will be crucial for long-term value creation.

What we're watching

Clinical Progress
The success of CUE-401’s IND application and subsequent clinical trial results will be critical to validating Cue Biopharma’s Immuno-STAT® platform and attracting further investment.
Financial Sustainability
Given the company's current cash position and ongoing R&D expenses, the ability to secure additional funding or demonstrate revenue generation will be key to sustaining operations.
Collaboration Synergy
The integration of ImmunoScape’s cell therapy approach and Cue Biopharma’s Immuno-STAT® platform will need to demonstrate tangible progress to justify the upfront investment and potential royalty payments.

Related topics

Revenue Growth